United Therapeutics Corporation · Silver Spring, MD United States (NASDAQ: UTHR)
| 1040 Spring St. | Phone: 301-608-9292 |
| Silver Spring, MD | Fax: 301-608-9291 |
| 20910 | |
| United States | 
Map This Company |
United Therapeutics Corporation Rankings
 #43 in FORTUNE's Fastest-Growing Companies (September 2011) | S&P 400 |
More Companies in These Related Industries: Pharmaceutical Preparation MfgCompany Description
United Therapeutics hopes its products will be in vein. Its injectable drug Remodulin treats pulmonary hypertension, which affects the blood vessels between the heart and lungs. The product is marketed directly and through distributors in North America, Europe, and other regions. Other hypertension treatments include Adcirca and Tyvaso. The company's development pipeline includes additional treatments for cardiovascular disease, as well as various cancers, respiratory conditions, and infectious diseases. United Therapeutics has divested its cardiac monitoring division.
United Therapeutics Corporation Reports
No subscription, no problem.
Download presentation-ready reports. From company profiles to the competitive landscape, Hoover's offers immediate access to individual reports.
Financials
| Company Type | Public - NASDAQ: UTHR Headquarters |
|---|---|
| Fiscal Year-End | December |
| 2011 Employees | 543 |
Executives
29 executives listed for United Therapeutics Corporation's Silver Spring, MD location.
| Chairman and CEO | Martine Rothblatt | |
|---|---|---|
| Vice Chairman | Christopher Patusky | |
| President, COO, and Director | Roger Jeffs |